Cerebrolysin 60MG
$49.00
Cerebrolysin is a unique neurotrophic peptide preparation derived from porcine brain tissue through a proprietary enzymatic breakdown process. This complex mixture consists of approximately 25% low molecular weight peptides (up to 10 kDa) and 75% free amino acids, designed to mimic the action of endogenous neurotrophic factors that support neuronal survival, growth, and plasticity.
49 Athena Points with this purchaseIn stock
Overview
Cerebrolysin is a unique neurotrophic peptide preparation derived from porcine brain tissue through a proprietary enzymatic breakdown process. This complex mixture consists of approximately 25% low molecular weight peptides (up to 10 kDa) and 75% free amino acids, designed to mimic the action of endogenous neurotrophic factors that support neuronal survival, growth, and plasticity.
Developed by EVER Neuro Pharma (formerly Ebewe Pharmaceuticals) in Austria, Cerebrolysin has been used clinically in over 50 countries worldwide, primarily in Europe, Asia, and South America, for the treatment of stroke, traumatic brain injury, and dementia including Alzheimer’s disease. While not approved in the United States, it represents one of the most extensively studied neuroprotective compounds globally.
Neurotrophic Concept
The rationale behind Cerebrolysin is based on the neurotrophic hypothesis – the concept that brain-derived growth factors are essential for neuronal survival, differentiation, and synaptic plasticity throughout life, and that supplementing these factors may protect against neurodegeneration and promote recovery from brain injury. Unlike single-molecule drugs, Cerebrolysin provides a complex mixture of bioactive peptides that may act synergistically through multiple neurotrophic pathways.
The peptide fraction of Cerebrolysin contains fragments with structural and functional similarities to brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), ciliary neurotrophic factor (CNTF), and other endogenous neurotrophins, potentially allowing it to engage multiple neurotrophin receptor systems simultaneously.
Mechanism of Action
Cerebrolysin exerts its neuroprotective and neurotrophic effects through multiple interconnected mechanisms that collectively support neuronal survival, synaptic function, and brain plasticity.
Neurotrophic Signaling
The peptide mixture activates neurotrophin receptor signaling pathways, particularly TrkA and TrkB receptors that mediate the effects of NGF and BDNF respectively. Activation of these receptors triggers intracellular cascades including the PI3K/Akt survival pathway, the MAPK/ERK pathway involved in synaptic plasticity and gene expression, and the PLCγ pathway affecting calcium signaling and neurotransmission.
Anti-Apoptotic Effects
Cerebrolysin protects neurons from programmed cell death (apoptosis) through multiple mechanisms: upregulation of anti-apoptotic proteins such as Bcl-2 and Bcl-xL, downregulation of pro-apoptotic proteins including Bax and caspases, protection of mitochondrial membrane integrity and prevention of cytochrome c release, and reduction of oxidative stress and free radical damage that trigger apoptotic cascades.
Synaptic Plasticity Enhancement
The compound enhances synaptic function and plasticity by promoting synaptogenesis (formation of new synaptic connections), increasing dendritic branching and spine density, modulating long-term potentiation (LTP) – the cellular mechanism underlying learning and memory, enhancing neurotransmitter release and receptor sensitivity, and supporting axonal growth and regeneration.
Neuroinflammation Modulation
Cerebrolysin modulates neuroinflammatory responses by reducing microglial activation and pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α), promoting anti-inflammatory responses, and protecting against excitotoxic damage from excessive glutamate release – a major contributor to neuronal death in stroke and brain injury.
Metabolic Support
The peptide mixture supports neuronal energy metabolism by enhancing glucose utilization, protecting mitochondrial function, improving cerebral blood flow and oxygen delivery, and reducing the metabolic consequences of ischemia and hypoxia.
Research Findings
Cerebrolysin has been the subject of extensive preclinical and clinical research spanning several decades, with hundreds of published studies examining its effects in various neurological conditions.
Stroke Research
Multiple clinical trials have evaluated Cerebrolysin in acute ischemic stroke. A Cochrane systematic review identified several randomized controlled trials, with some studies showing improvements in functional outcomes and neurological recovery when Cerebrolysin was administered in the acute post-stroke period. The CASTA trial (Cerebrolysin Acute Stroke Treatment in Asia) enrolled over 1,000 patients and found trends toward improved outcomes, though the primary endpoint did not reach statistical significance.
Preclinical stroke research has demonstrated that Cerebrolysin reduces infarct volume in animal models of cerebral ischemia, protects penumbral tissue (the at-risk zone surrounding the stroke core), promotes angiogenesis and neurogenesis in damaged brain regions, and enhances functional recovery after experimental stroke.
Traumatic Brain Injury (TBI)
Studies in traumatic brain injury have shown cognitive improvements and enhanced recovery in patients receiving Cerebrolysin compared to placebo. Research in animal TBI models demonstrates reduced brain edema and secondary injury, protection of the blood-brain barrier, decreased neuroinflammation and oxidative damage, and improved cognitive and motor outcomes.
Alzheimer’s Disease and Dementia
Clinical trials in Alzheimer’s disease have shown modest but consistent improvements in cognitive function, particularly in attention, memory, and global clinical impression scores. A meta-analysis of Cerebrolysin trials in dementia found statistically significant benefits compared to placebo on cognitive measures. The peptide’s ability to engage neurotrophic pathways relevant to Alzheimer’s pathology (BDNF signaling, synaptic plasticity) provides mechanistic rationale for these findings.
Other Neurological Applications
Research has also explored Cerebrolysin’s potential benefits in vascular dementia, diabetic neuropathy, Parkinson’s disease, and pediatric neurodevelopmental conditions, with varying degrees of evidence.
Research Applications
- Stroke recovery and neuroprotection research
- Traumatic brain injury rehabilitation studies
- Alzheimer’s disease and dementia research
- Cognitive enhancement and nootropic studies
- Neurotrophic factor signaling research
- Synaptic plasticity and neuroplasticity studies
- Neuroregeneration and neurogenesis research
- Vascular dementia and cerebrovascular disease studies
- Neuroprotection mechanism research
- Brain injury recovery optimization studies
Safety Profile
Cerebrolysin has an extensive safety record from decades of clinical use in over 50 countries and numerous clinical trials involving thousands of patients. The overall safety profile is favorable, with most adverse events being mild and transient.
Common Adverse Effects
The most frequently reported side effects include injection site reactions (as Cerebrolysin is administered intravenously or intramuscularly), headache, dizziness, and mild gastrointestinal symptoms such as nausea. These effects are typically self-limiting and rarely require discontinuation of treatment.
Allergic Reactions
As a porcine-derived biological product, there is a theoretical risk of allergic or hypersensitivity reactions, though serious allergic events are rare in clinical practice. Patients with known pork allergies should avoid Cerebrolysin. Mild allergic symptoms such as skin rash or pruritus have been occasionally reported.
Clinical Trial Safety Data
Systematic reviews and meta-analyses of Cerebrolysin clinical trials have not identified significant safety concerns compared to placebo. The Cochrane review of Cerebrolysin in acute stroke noted that adverse event rates were similar between treatment and control groups. Long-term safety data from extended treatment protocols appears reassuring.
Regulatory Considerations
Cerebrolysin is approved for clinical use in many countries but not in the United States, where the FDA has not granted marketing authorization. This reflects differences in regulatory requirements rather than specific safety concerns. The product is manufactured under pharmaceutical GMP standards by EVER Neuro Pharma.
As with any biologically-derived product, quality control, proper storage, and administration by qualified healthcare providers are essential for safe use. Cerebrolysin should not be mixed with balanced amino acid solutions due to potential incompatibilities.
Frequently Asked Questions
What is 5-Amino-1MQ and how does it work?
5-Amino-1MQ is a synthetic small-molecule compound studied for its ability to inhibit the enzyme nicotinamide N-methyltransferase, commonly referred to as NNMT. This enzyme plays a regulatory role in metabolic signaling and energy balance within cells. By limiting NNMT activity, 5-Amino-1MQ helps preserve nicotinamide, a key precursor involved in NAD+ production, allowing researchers to examine how cellular energy utilization and metabolic efficiency may be influenced.
What is 5-Amino-1MQ used for in research settings?
In professional research environments, 5-Amino-1MQ is examined for its role in metabolic regulation and cellular energy pathways. Scientists study this compound to better understand how enzyme inhibition can impact fat metabolism, glucose utilization, and overall metabolic signaling. Its targeted mechanism makes it useful for exploring metabolic adaptation and energy balance models.
How does 5-Amino-1MQ affect NAD+ levels?
NNMT consumes nicotinamide during methylation processes, which can reduce availability for NAD+ synthesis. By inhibiting NNMT, 5-Amino-1MQ allows more nicotinamide to remain accessible for NAD+ production. NAD+ is a critical coenzyme involved in mitochondrial activity, redox reactions, and cellular communication, making this pathway an area of significant scientific interest.
Is 5-Amino-1MQ associated with fat metabolism research?
Yes, 5-Amino-1MQ is frequently studied in the context of fat metabolism and body composition research. By influencing metabolic enzymes rather than appetite or stimulatory pathways, it provides researchers with a tool to examine how cells regulate fat storage and energy expenditure. This has made it a topic of interest in studies focused on metabolic efficiency and adipose signaling.
How is 5-Amino-1MQ different from traditional metabolic compounds?
Unlike many conventional metabolic compounds that rely on hormonal stimulation or nervous system activation, 5-Amino-1MQ operates at the enzymatic level. Its mechanism centers on NNMT inhibition, offering a more targeted approach to studying metabolic regulation. This distinction allows researchers to explore metabolic changes without introducing stimulant-based variables.
Why is 5-Amino-1MQ gaining attention in metabolic research?
5-Amino-1MQ is gaining attention because it addresses metabolism at a foundational biochemical level. As interest in NAD+, mitochondrial health, and metabolic flexibility continues to grow, compounds that influence these pathways through enzyme regulation are becoming increasingly relevant. Its specificity and consistency make it a valuable compound for advanced metabolic research models.
SURPASS & SURMOUNT Clinical Programs
SURPASS-1: Monotherapy Efficacy
478 treatment-naïve T2D patients randomized to GLP2-T (5/10/15 mg) vs placebo for 40 weeks:
- HbA1c reductions: -1.87% (5 mg), -1.89% (10 mg), -2.07% (15 mg) vs +0.04% placebo
- 87-97% of participants achieved HbA1c <7% (vs 20% placebo)
- Weight loss: -7.0 to -9.5 kg dose-dependent reduction
- Superior glycemic control without background medications
SURPASS-2: Head-to-Head vs Semaglutide
1,879 T2D patients on metformin randomized to GLP2-T vs GLP1-S 1 mg for 40 weeks:
- GLP2-T 15 mg reduced HbA1c -2.46% vs -1.86% with GLP1-S (p<0.001)
- Weight loss: -11.2 kg (15 mg) vs -5.7 kg GLP1-S
- 62% achieved dual endpoint (HbA1c <5.7% + ≥5% weight loss) vs 18% GLP1-S
- Established dual-agonist superiority over selective GLP-1RAs
SURMOUNT-1: Obesity Pharmacotherapy
2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities, 72 weeks:
- Mean weight reduction: -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) vs -3.1% placebo
- 89% of participants on 10 mg achieved ≥5% weight loss (vs 28% placebo)
- 50% achieved ≥20% weight loss on 10/15 mg doses—unprecedented in pharmacotherapy
- Significant improvements in cardiometabolic markers (BP, lipids, inflammatory markers)
SURMOUNT-2: Obesity + Diabetes
938 adults with obesity/overweight and type 2 diabetes on metformin ± SGLT2i/sulfonylurea:
- Weight loss: -12.8% (10 mg), -14.7% (15 mg) vs -3.2% placebo at 72 weeks
- HbA1c reduction: -2.07% (10 mg), -2.11% (15 mg) vs -0.51% placebo
- Dual benefit in challenging population with metabolic comorbidity
- Sustained effects maintained through study completion
Cardiovascular Risk Reduction
Post-hoc analysis and meta-analysis of cardiovascular outcomes across trials:
- Systolic BP reduction: -5 to -8 mmHg across doses
- LDL cholesterol: -7 to -10 mg/dL improvement
- High-sensitivity CRP: -43% reduction (inflammatory marker)
- SURPASS-CVOT outcomes trial ongoing (results expected 2024-2025)
Renal & Hepatic Effects
Secondary and exploratory endpoints from pooled SURPASS/SURMOUNT data:
- Urinary albumin-to-creatinine ratio reduction: -27% vs baseline
- eGFR preservation in participants with baseline CKD
- ALT/AST reductions suggest hepatoprotective effects in NAFLD
- Mechanistic studies ongoing to elucidate organ-protective pathways
Structural & Pharmacological Insights
Receptor Binding Modes
Cryo-electron microscopy structures reveal GLP2-T engages both GIPR and GLP-1R through their orthosteric binding pockets in the N-terminal extracellular domain. The C20 fatty acid modification does not directly contact the receptor but positions the peptide for enhanced G protein coupling efficiency.
Transmembrane Domain Conformations
Active-state receptor structures demonstrate GLP2-T stabilizes outward movement of transmembrane helix 6, creating Gs binding interface geometry. The bias toward cAMP signaling at GLP-1R correlates with reduced conformational changes in intracellular loop 3, limiting β-arrestin recruitment.
Islet Synergy Mechanisms
Co-infusion studies demonstrate GIP + GLP-1 produce supraadditive insulin secretion (>2x individual effects). GLP2-T recapitulates this synergy in single-molecule format. Mechanistically, parallel cAMP generation from both receptors amplifies PKA-dependent phosphorylation of KATP channels and voltage-gated calcium channels, maximizing glucose-stimulated insulin secretion.
GIPR Requirement for Efficacy
Genetic ablation studies in human islets confirm GLP2-T’s insulinotropic actions require functional GIPR. In GIPR knockout models, GLP2-T loses ~60% of glucose-lowering capacity, demonstrating GIP signaling is non-redundant despite GLP-1R activation.
Adverse Event Profile
Gastrointestinal (Most Common)
Nausea (12-18%), diarrhea (12-14%), vomiting (2-6%), constipation (5-7%). Predominantly mild-to-moderate severity, highest incidence during dose escalation, typically resolving within 4-8 weeks. Discontinuation rate: 4-7% vs 2% placebo.
Injection Site Reactions
Mild erythema, pruritus, or induration reported in 1-3% of participants. Rotating injection sites (abdomen, thigh, upper arm) minimizes local reactions. No serious injection-related adverse events.
Hypoglycemia Risk
Glucose-dependent mechanism results in low intrinsic hypoglycemia risk when used as monotherapy (<1%). Risk increases to 5-8% when combined with sulfonylureas or insulin. No severe hypoglycemia events in monotherapy trials.
Thyroid C-Cell Concerns
GLP-1RAs carry theoretical medullary thyroid carcinoma risk based on rodent models. Human relevance uncertain—no increased calcitonin elevations or thyroid neoplasia in clinical trials. Contraindicated in MEN2 or personal/family history of MTC.
Cardiovascular Effects
Heart rate increases: +2 to +4 bpm mean change. Mechanism likely involves increased sympathetic tone from weight loss. No increased atrial fibrillation risk observed. Blood pressure reductions (-5 to -8 mmHg systolic) likely cardiovascular-protective.
Rare Serious Events
Acute pancreatitis: <0.2% incidence (similar to placebo rates). Gallbladder disease: 1.5% vs 0.7% placebo, likely secondary to rapid weight loss. Diabetic retinopathy worsening: rare, associated with rapid glycemic improvement in patients with pre-existing retinopathy.
